| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 5g |
|
| Targets |
Ca2+ signaling pathway [2]
|
|---|---|
| ln Vitro |
Treatment with L-Ornithine hydrochloride (1 mM, 5 mM, 10 mM) exerted a protective effect on human proximal tubular cells (HK-2 cells) against cisplatin-induced injury, as evidenced by increased cell viability and reduced apoptotic rate. The protective effect was mediated by activating Ca2+ signaling, which was confirmed by the fact that pre-treatment with Ca2+ chelator BAPTA-AM or PLC inhibitor U73122 abolished the protective effect. Western blot analysis showed that L-Ornithine hydrochloride upregulated the expression of anti-apoptotic protein Bcl-2 and downregulated the expression of pro-apoptotic protein Bax, while also increasing the phosphorylation of PLCγ1 and IP3R1, key molecules in the PLC-IP3-Ca2+ signaling pathway. Fluorescence imaging revealed that L-Ornithine hydrochloride increased intracellular Ca2+ concentration in HK-2 cells in a dose-dependent manner[2]
|
| ln Vivo |
A randomized, double-blind, placebo-controlled crossover study was conducted on 12 healthy male volunteers (age 23.5 ± 2.1 years, body mass 75.3 ± 6.2 kg, height 181.2 ± 5.4 cm). Participants ingested L-Ornithine hydrochloride at a dose of 0.1 g/kg body weight or placebo (maltodextrin) dissolved in 250 mL of water 60 minutes before performing an intermittent maximal anaerobic cycle ergometer test. The test consisted of 10 bouts of 10-second maximal sprints separated by 50 seconds of passive recovery. No significant differences were observed between L-Ornithine hydrochloride and placebo groups in peak power, mean power, total work output, or fatigue index during the sprint test. However, 24 hours after exercise, the L-Ornithine hydrochloride group showed a significant reduction in perceived muscle soreness (visual analog scale score: 3.2 ± 1.1 vs. 4.5 ± 1.3 in placebo group) and a trend towards lower serum creatine kinase levels (285 ± 42 U/L vs. 321 ± 48 U/L in placebo group, P = 0.07)[1]
|
| Cell Assay |
HK-2 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% antibiotics, maintained at 37°C in a humidified atmosphere with 5% CO2. Cells were seeded into 96-well plates (5 × 103 cells/well) or 6-well plates (2 × 105 cells/well) and allowed to adhere for 24 hours. For cell viability and apoptosis assays, cells were pre-treated with different concentrations of L-Ornithine hydrochloride (1 mM, 5 mM, 10 mM) for 2 hours, followed by exposure to cisplatin (20 μM) for 24 hours. Cell viability was measured using the CCK-8 assay, and apoptotic cells were detected by Annexin V-FITC/PI double staining followed by flow cytometric analysis. For Ca2+ signaling detection, cells were loaded with Fluo-4 AM fluorescent probe for 30 minutes at 37°C, washed three times with PBS, and then treated with L-Ornithine hydrochloride (10 mM); intracellular Ca2+ fluorescence intensity was monitored in real-time using a fluorescence microscope or microplate reader. For Western blot analysis, cells were harvested after treatment, lysed in RIPA buffer containing protease and phosphatase inhibitors, and protein extracts were separated by SDS-PAGE, transferred to PVDF membranes, incubated with primary antibodies against Bcl-2, Bax, PLCγ1, p-PLCγ1, IP3R1, and β-actin, followed by secondary antibody incubation and chemiluminescent detection[2]
|
| References |
|
| Additional Infomation |
L-ornithine monochloride/ornithine is an L-α-amino acid. L-ornithine hydrochloride is a naturally occurring amino acid derivative that has been proposed as a dietary supplement for improving athletic performance and promoting recovery [1]. L-ornithine hydrochloride protects human proximal tubular cells from cisplatin-induced damage by activating the PLC-IP3-Ca2+ signaling pathway, which regulates the expression of apoptosis-related proteins, thereby inhibiting apoptosis [2].
|
| Molecular Formula |
C5H13CLN2O2
|
|---|---|
| Molecular Weight |
168.6219
|
| Exact Mass |
168.066
|
| CAS # |
3184-13-2
|
| Related CAS # |
6211-16-1
|
| PubChem CID |
76654
|
| Appearance |
White to off-white solid powder
|
| Density |
1.57
|
| Boiling Point |
308.7ºC at 760 mmHg
|
| Melting Point |
245 °C (dec.)(lit.)
|
| Flash Point |
140.5ºC
|
| Index of Refraction |
24 ° (C=4, 6mol/L HCl)
|
| LogP |
1.339
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
10
|
| Complexity |
95
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C(C[C@@H](C(=O)O)N)CN.Cl
|
| InChi Key |
GGTYBZJRPHEQDG-WCCKRBBISA-N
|
| InChi Code |
InChI=1S/C5H12N2O2.ClH/c6-3-1-2-4(7)5(8)9;/h4H,1-3,6-7H2,(H,8,9);1H/t4-;/m0./s1
|
| Chemical Name |
(2S)-2,5-diaminopentanoic acid;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.9305 mL | 29.6525 mL | 59.3049 mL | |
| 5 mM | 1.1861 mL | 5.9305 mL | 11.8610 mL | |
| 10 mM | 0.5930 mL | 2.9652 mL | 5.9305 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
